View More View Less
  • 1 Bajcsy-Zsilinszky Kórház Onkológiai Osztály Budapest Maglódi út 89–91. 1106
  • | 2 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika, Geriátriai Tanszéki Csoport Budapest
  • | 3 Szent Imre Egyetemi Oktatókórház Nephrologia-Hypertonia Profil és Aktív Geriátriai Részleg Budapest
  • | 4 B. Braun Avitum Zrt. Dialízis Hálózat 1. Sz. Dialízisközpont Budapest
Open access

Cross Mark

Az utóbbi időben ellentmondó adatok jelentek meg az angiotenzinreceptor-blokkolók daganatképződést fokozó hatásairól. A szakirodalomban az ellentmondásoknak számos oka lehet, többek között: rosszul tervezett vizsgálat, illetve hibás interpretáció. Tekintettel a kezelt hypertoniás betegek nagy számára, különösen fontos, hogy a magas vérnyomás kezelésére használt gyógyszerek onkológiai biztonságosságának kérdésében tisztán lássunk. Jelen közlemény a rendelkezésre álló adatok áttekintésével igyekszik választ adni a felmerült kérdésekre. Az angiotenzinreceptor-blokkolók daganatellenes hatásának, mai tudásunk szerint, nagyobb az esélye, mint a karcinogenezist fokozó hatásnak. Erre mutatnak azok az onkológiai vizsgálatok, amelyekben az angiotenzinreceptor-blokkoló terápiát kiegészítő kezelésnek javasolják a kemoterápia mellé hasnyálmirigy-, nyelőcső- és gyomordaganatok esetén. Orv. Hetil., 2015, 156(11), 423–430.

  • Lawes, C. M., Vander Hoorn, S., Rodgers, A.: Global burden of blood-pressure-related disease, 2001. Lancet, 2008, 371(9623), 1513–1518.

  • Globocan 2008. Cancer incidence and mortality worldwide. WHO, International Agency for Research on Cancer. http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php

  • Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. WHO, International Agency for Research on Cancer. http://globocan.iarc.fr/Default.aspx

  • Kiss, I., Telekes, A.: Cancer and hypertension. In: Farsang, Cs. (ed.): Textbook of hypertension. [Daganatos betegségek és hypertonia. In: Farsang, Cs. (szerk.): A hypertonia kézikönyve.] Medintel Kiadó, Budapest, 2002. [Hungarian]

  • Sipahi, I., Debanne, S. M., Rowland, D. Y., et al.: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol., 2010, 11(7), 627–636.

  • Farsang, Cs.: On the safety of angiotensinreceptor blockers – A new attack on this drug class. [Az angiotenzinreceptor-blokkolók biztonságosságáról. Újabb támadás e gyógyszercsoport ellen.] Lege Artis Med., 2010, 20(8), 473–477. [Hungarian]

  • Dézsi, Cs. A.: In the mirror of clinical studies: Angiotensin II receptor blockers and risk of cancer. [A klinikai vizsgálatok tükrében: Az angiotensin-II-receptor-blokkolók és a rák kockázata.] Háziorvosi Továbbképző Szemle, 2013, 18(8), 521–526. [Hungarian]

  • Volpe, M., Azizi, M., Danser, A. H., et al.: Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur. Heart J., 2011, 32(1), 19–22.

  • George, A. J., Thomas, W. G., Hannan, R. D.: The renin-angiotensin system and cancer: old dog, new tricks. Nat. Rev. Cancer, 2010, 10(11), 745–759.

  • Deshayes, F., Nahmias, C.: Angiotensin receptors: a new role in cancer? Trends Endocrinol. Metab., 2005, 16(7), 293–299.

  • Chung, O., Csikós, T., Unger, T.: Angiotensin II receptor pharmacology and AT1-receptor blockers. J. Hum. Hypertens., 1999, 13(Suppl. 1), S11–S20.

  • Chung, O., Kühl, H., Stoll, M., et al.: Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int. 1998, 67(Suppl.), S95–S99.

  • Egami, K., Murohara, T., Shimada, T., et al.: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest., 2003, 112(1), 67–75.

  • Suzuki, Y., Ruiz-Ortega, M., Lorenzo, O., et al.: Inflammation and angiotensin II. Int. J. Biochem. Cell Biol., 2003, 35(6), 881–900.

  • Sano, H., Hosokawa, K., Kidoya, H., et al.: Negative regulation of VEGF-induced vascular leakage by blockade of angiotenzin II type 1 receptor. Arterioscler. Thromb. Vasc. Biol., 2006, 26(12), 2673–2680.

  • Ager, E. I., Neo, J., Cristophi, C.: The renin-angiotensin system and malignancy. Carcinogenesis, 2008, 29(9), 1675–1684.

  • Silvestre, J. S., Tamarat, R., Senbonmatsu, T., et al.: Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ. Res., 2002, 90(10), 1072–1079.

  • Link, W. T., De Felice, A.: An FDA overview of rodent carcinogenicity studies of angiotensin II AT-1 receptor blockers: Pulmonary adenomas and carcinomas. Regul. Toxicol. Pharmacol., 2014, 70(2), 555–563.

  • Gong, Q., Davis, M., Chipitsyna, G., et al.: Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas, 2010, 39(5), 581–594.

  • Uemura, H., Ishiguro, H., Nagashima, Y., et al.: Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol. Cancer Ther., 2005, 4(11), 1699–1709.

  • Suganuma, T., Ino, K., Shibata, K., et al.: Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis and peritoneal dissemination. Clin. Cancer Res., 2005, 11(7), 2686–2694.

  • Schupp, N., Schmid, U., Rutkowski, P., et al.: Angiotenzin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am. J. Physiol. Renal Physiol., 2007, 292(5), F1427–F1434.

  • Kinoshita, J., Fushida, S., Harada, S., et al.: Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and surviving. Int. J. Oncol., 2009, 34(6), 1573–1582.

  • Herr, D., Rodewald, M., Fraser, H. M., et al.: Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol. Oncol., 2008, 109(3), 418–425.

  • Arafat, H. A., Gong, Q., Chipitsyna, G., et al.: Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J. Am. Coll. Surg., 2007, 204(5), 996–1005.

  • Noguchi, R., Yoshiji, H., Ikenaka, Y., et al.: Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol. Rep., 2009, 22(2), 355–360.

  • Redondo-Müller, M. A., Stevanovic-Walker, M., Barker, S., et al.: Anti-cancer actions of recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr. Relat. Cancer, 2008, 15(1), 277–288.

  • Uemura, H., Ishiguro, H., Kubota, Y.: Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev. Med. Chem., 2006, 6(7), 835–844.

  • Ino, K., Shibata, K., Kajiyama, H., et al.: Manipulating the angiotensin system – new approaches to the treatment of solid tumors. Expert Opin. Biol. Ther., 2006, 6(3), 243–255.

  • Da, Y. J., Yuan, W. D., Zhu, L. F., et al.: Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer. Arzneimittelforschung, 2012, 62(12), 637–643.

  • Takahashi, S., Uemura, H., Seeni, A., et al.: Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate, 2012, 72(14), 1559–1572.

  • Funao, K., Matsuyama, M., Kawahito, Y., et al.: Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol. Rep., 2008, 20(2), 295–300.

  • Koyama, N., Nishida, Y., Ishii, T., et al.: Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS ONE, 2014, 9(3), e93050.

  • Li, J., Chen, L., Yu, P., et al.: Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells. Molecules, 2014, 19(3), 2862–2876.

  • Verhoest, G., Dolley-Hitze, T., Jouan, F., et al.: Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. BioMed Res. Int., 2014, 2014, 901371.

  • Pfeffer, M. A., Swedberg, K., Granger, C. B., et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362(9386), 759–766.

  • Bangalore, S., Kumar, S., Kjeldsen, S. E., et al.: Antihypertensive drugs and risk of cancer: network meta analyses and trial sequential analyses of 324,168 participants from randomized trials. Lancet Oncol., 2011, 12(1), 65–82.

  • ARB Trialists Collaboration: Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens., 2011, 29(4), 623–635.

  • Pasternak, B., Svanström, H., Callréus, T., et al.: Use of angiotensin receptor blockers and the risk of cancer. Circulation, 2011, 123(16), 1729–1736.

  • Opelz, G., Döhler, B.: Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report. Am. J. Transplant., 2011, 11(11), 2483–2489.

  • Sugiura, R., Ogawa, H., Oka, T., et al.: Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). Am. J. Cardiol., 2012, 109(4), 576–580.

  • Huang, C. C., Chan, W. L., Chen, Y. C., et al.: Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am. J. Cardiol., 2011, 107(7), 1028–1033.

  • Chang, C. H., Lin, J. W., Wu, L. C., et al.: Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J. Clin. Oncol., 2011, 29(22), 3001–3007.

  • Chiang, Y. Y., Chen, K. B., Tsai, T. H., et al.: Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study. J. Clin. Hypertens (Greenwich), 2014, 16(1), 27–33.

  • Azoulay, L., Assimes, T. L., Yin, H., et al.: Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS ONE 2012, 7(12), e50893.

  • Chin, H. J., Oh, S. W., Goo, H. S., et al., Members of the PREMIER Group: Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J. Korean Med. Sci., 2011, 26(1), 59–66.

  • Yuge, K., Miyajima, A., Tanaka, N., et al.: Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann. Surg. Oncol., 2012, 19(12), 3987–3993.

  • Rao, G. A., Mann, J. R., Shoaibi, A., et al.: Angiotensin receptor blockers: are they related to lung cancer? J. Hypertens., 2013, 31(8), 1669–1675.

  • Rao, G. A., Mann, J. R., Bottai, M., et al.: Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J. Clin. Pharmacol., 2013, 53(7), 773–778.

  • Holmes, S., Griffith, E. J., Musto, G., et al.: Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol., 2013, 37(6), 881–885.

  • Sørensen, G. V., Ganz, P. A., Cole, S. W., et al.: Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J. Clin. Oncol., 2013, 31(18), 2265–2272.

  • Makar, G. A., Holmes, J. H., Yang, Y. X.: Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J. Natl. Cancer Inst., 2014, 106(2), djt374.

  • Engineer, D. R., Burney, B. O., Hayes, T. G., et al.: Exposure to ACEI/ARB and β-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl. Oncol., 2013, 6(5), 539–545.

  • Cardwell, C. R., Mc Menamin, Ú. C., Hicks, B. M., et al.: Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med., 2014, 12, 28. http://www.biomedcentral.com/1741-7015/12/28

  • Mc Menamin, Ú. C., Murray, L. J., Cantwell, M. M., et al.: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control, 2012, 23(2), 221–230.

  • Nakai, Y., Isayama, H., Ijichi, H., et al.: Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer, 2010, 103(11), 1644–1648.

  • Kim, S. T., Park, K. H., Oh, S. C., et al.: How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology, 2012, 83(6), 354–360.

  • Chen, Y. H., Huang, C. H., Lu, H. I., et al.: Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma. J. Renin Angiotensin Aldosterone Syst., 2014 Jun 24. pii: 1470320314535275. [Epub ahead of print]

  • Chauhan, V. P., Martin, J. D., Liu, H., et al.: Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun., 2013, 4, 2516. www.nature.com/naturecommunications

  • Meradith, P.: Comparative ARB pharmacology. Br. J. Cardiol., 2010, 17(Suppl. 2), S3–S5.

  • Egan, G., Lee, J., Minhas, R., et al.: Does outcome reporting bias “cause” cancer? Risks associated with hidden data on angiotensin receptor blockers. Can. J. Hosp. Pharm., 2012, 65(5), 387–393.

  • FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs – angiotensin receptor blockers (ARBs). www.fda.gov/Drugs/DrugsSafety/ucm257516.htm

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 49 48 5
PDF Downloads 106 106 2